Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

4,000-Patient Milestone in Medtronic CoreValve Program Also Expected to Coincide with EuroPCR09 Medtronic, Inc. (NYSE: MDT), announced planned highlights of new data presentations scheduled for the 2009 PCR meeting that feature the company’s cardiovascular innovations. From late breaking clinical trials, extensive new data on the Endeavor Drug-Eluting Stent (DES) will be presented, which shows unprecedented long-term efficacy for a DES.

Also featured are new data on Medtronic’s CoreValve® transfemoral and subclavian aortic valve system. Medtronic also anticipates that PCR 2009 will coincide with the 4,000th successful CoreValve implant.

Important data on the long-term efficacy and durable safety of the Endeavor DES will be presented in the following late-breaking clinical trial sessions:

Tuesday, May 19

• ENDEAVOR II and ENDEAVOR Pooled five-year data by Dr. D. Kandzari

Thursday , May 21

• DATE Registry on early discontinuation of antiplatelet therapy by Dr. H. Gwon.

Additional data related to Medtronic’s cardiovascular medical technologies will also be released in the following oral and poster contributions starting Tuesday, May 19:

• E-Five one-year ACS subset data by Prof. M. Rothman
• Medtronic CoreValve subclavian transcatheter aortic valve replacement by Dr. Jean-Claude Laborde
• E-Five one- and two-year data by Prof. I. Meredith

In addition, Medtronic will feature highlights of its current and future cardiovascular innovations at PCR (booth numbers D04 and F09). PCR takes place in Barcelona, Spain, May 19–22.

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

Source: Medtronic